NervGen Pharma (TSE:NGEN) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NervGen Pharma is nearing the completion of enrollment for its Phase 1b/2a clinical trial of NVG-291 targeting spinal cord injuries, while also advancing preclinical studies of NVG-300 in ischemic stroke, ALS, and SCI. The company is focusing on innovative trial designs and strategic pipeline diversification to enhance future partnering opportunities.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
